Commission authorises mRNA vaccine against common respiratory virus
The Commission has authorised the mRNA vaccine ‘mResvia’, to immunise adults over 60 years of age against lower respiratory tract disease, which is caused by respiratory syncytial virus (RSV) infection. RSV is a common respiratory virus, usually with mild symptoms but has potential serious consequences for vulnerable people, including older adults. The authorisation of mResvia comes ahead of …